The CNS is protected by a network of interfaces rather than by a single wall. The best-known structure is the blood–brain barrier, formed primarily by tightly connected endothelial cells lining the brain’s blood vessels. These cells work with pericytes, astrocytes and components of the extracellular matrix to regulate the passage of substances from the bloodstream into the neural tissue. Tight junctions between endothelial cells limit the movement of water-soluble molecules, while transport proteins selectively control the entry and removal of nutrients, metabolites and drugs. Additional interfaces, including the blood–cerebrospinal fluid barrier and barriers associated with the meninges, create separate compartments around the brain. Together, these systems help prevent toxins, pathogens and uncontrolled immune activity from disturbing the CNS.

This organization has important consequences for immune surveillance. In many organs, immune cells continuously patrol tissue, enter sites of inflammation and rapidly encounter abnormal cells. In the healthy brain parenchyma, however, immune access is more tightly regulated. Immune monitoring is concentrated at CNS borders, particularly in the subarachnoid space surrounding the brain and spinal cord, the cerebrospinal fluid and perivascular spaces that accompany blood vessels. These regions function as strategic observation points, allowing immune mediators and cells to monitor the nervous system without exposing neurons to the potentially damaging effects of unrestricted inflammation. The result is a carefully controlled form of surveillance that protects brain function but may be poorly suited to detecting tumours developing deep within the neural tissue.

Gliomas arise from, or resemble, cells within the CNS parenchyma and can grow through regions that are naturally shielded from circulating immune components. As tumour cells expand, they may therefore remain outside the main routes used by immune cells to enter or inspect the brain. This spatial separation creates a major obstacle for immunotherapies. Immune checkpoint inhibitors, for example, are designed to release molecular brakes that prevent T cells from attacking cancer. Yet removing those brakes has limited value if activated T cells cannot efficiently enter the tumour or remain unable to penetrate its surrounding tissue. The same principle applies to cancer vaccines, which stimulate tumour-specific immune responses, and to cellular therapies that depend on the physical delivery of immune cells to malignant sites.

Adoptive T cell therapies illustrate the problem particularly clearly. Chimeric antigen receptor, or CAR, T cells are engineered to recognize specific molecules on cancer cells, while T cell receptor, or TCR, transgenic cells are modified to detect tumour-derived peptides presented by major histocompatibility complex molecules. Once activated, these cells must circulate, cross relevant CNS interfaces, move through the tumour microenvironment and maintain their function in a setting that can suppress immune activity. Brain barriers can restrict each stage. They may limit the number of therapeutic cells entering the CNS, control the molecules that reach the tumour and create compartmentalized environments in which immune cells receive incomplete or altered signals. A powerful T cell product may therefore show striking activity in laboratory systems while producing weaker responses in patients with parenchymal gliomas.

The review also highlights that gliomas are not passive occupants of the brain’s protected environment. Emerging evidence suggests that these tumours can actively remodel barrier function, reinforcing the separation between the tumour and the immune system. Cancer cells and associated stromal or vascular cells may alter endothelial properties, modify extracellular matrix structures and influence the activity of astrocytes and pericytes. Such changes can affect vascular permeability, transport systems and the routes through which immune cells communicate with or enter the tumour. Importantly, barrier remodeling is not necessarily equivalent to simply making the blood–brain barrier “leaky.” A tumour may disrupt some barrier functions while preserving or intensifying others, producing a complex interface that permits selected molecules or cells to pass but continues to block effective immune access.

This complexity helps explain why the presence of blood vessels inside a glioma does not guarantee that immune therapies can reach their targets. Tumour-associated vessels are often structurally abnormal, yet their permeability and transport properties can vary across the same lesion. Some regions may display barrier breakdown, while neighbouring areas retain restrictive endothelial characteristics. The tumour microenvironment can also contain suppressive myeloid cells, altered glial cells and molecular signals that diminish T cell activation. In this setting, improved access alone may not be sufficient; therapy must account for the identity, activation state and distribution of the immune cells that arrive. Brain barriers should therefore be viewed as dynamic neuroimmunological interfaces rather than static obstacles.

These observations carry consequences for the design of clinical trials. Immunotherapy studies in glioma commonly focus on tumour genetics, antigen expression, T cell activity and radiographic changes. The authors argue that barrier status and CNS compartmentalization should also become central considerations. Researchers may need to determine whether a treatment reaches the relevant tumour regions, which barrier components regulate that access and how those properties change during disease progression or therapy. Biomarkers reflecting vascular transport, cerebrospinal fluid immune activity, perivascular inflammation or regional barrier function could eventually help identify patients most likely to respond. Treatment schedules might also need to be coordinated with approaches that influence barrier permeability or immune trafficking, although such interventions would have to preserve the protective functions of the CNS and avoid harmful neuroinflammation.

The perspective does not suggest that disrupting brain barriers indiscriminately would solve the problem. These structures are essential for neuronal survival, and uncontrolled opening could allow toxic substances, infectious agents or excessive immune activity into sensitive tissue. Any strategy aimed at improving access must therefore be precise, temporary and compatible with the brain’s physiological requirements. Future therapies may combine tumour-directed immune activation with methods that guide T cells toward CNS borders, enhance their passage through selected interfaces or alter the tumour-associated vasculature without damaging healthy neural tissue. Understanding how CAR T cells, TCR therapies, vaccines and checkpoint inhibitors interact with these barriers could also reveal why responses differ between patients whose tumours appear similar by conventional molecular classifications.

The central message is that successful glioma immunotherapy will require more than identifying the right tumour antigen or engineering a stronger immune cell. It will require understanding the routes that connect the bloodstream, the meninges, the cerebrospinal fluid, the perivascular spaces and the brain parenchyma, as well as the ways gliomas reshape those routes. By placing brain barriers at the centre of glioma immune surveillance, the new analysis frames treatment resistance as a problem of access, communication and compartmentalized biology. For patients with brain tumours, that shift could guide the development of immunotherapies designed not only to recognize cancer, but also to reach it.

Subject of Research: The role of CNS brain barriers in glioma immune surveillance and immunotherapy response.

Article Title: Brain barriers at the crossroads of glioma immune surveillance and immunotherapy response

Article References: Engelhardt, B., Platten, M. Brain barriers at the crossroads of glioma immune surveillance and immunotherapy response. Nature Reviews Cancer (2026). https://doi.org/10.1038/s41568-026-00960-w

Image Credits: AI Generated

DOI: 10.1038/s41568-026-00960-w

Keywords: Glioma, brain barriers, blood–brain barrier, CNS immune privilege, neuroimmunology, immune surveillance, immunotherapy, CAR T cells, TCR therapy, immune checkpoint inhibitors

The review, titled “Glioma Microenvironment: Cellular Crosstalk, Immunosuppression, and Novel Therapeutic Perspectives,” describes the tumor microenvironment as an active biological network rather than a passive structure surrounding cancer cells. Glioma cells release cytokines, chemokines, growth factors and extracellular-matrix-modifying enzymes that reshape neighboring cells. In response, immune and stromal cells alter their behavior in ways that can benefit the tumor. The result is a paradoxical state sometimes described as “inflammation without immunity”: immune cells accumulate in the tumor, but many become functionally suppressed and incapable of mounting an effective antitumor response.

Resident microglia, the brain’s innate immune sentinels, are among the first cells to be reprogrammed. Glioma-derived molecules such as Versican can push microglia toward a pro-tumorigenic phenotype. Once polarized, these cells may support invasion through matrix metalloproteinase-14, or MMP14, and other mediators including stress-inducible protein 1, secreted phosphoprotein 1 and epidermal growth factor. They can also contribute to immune suppression by expressing programmed death-ligand 1, or PD-L1, and transforming growth factor beta. These signals weaken local T-cell activity while helping malignant cells move through the surrounding brain tissue.

Circulating monocytes provide another major source of tumor-associated macrophages. Gliomas recruit these cells through chemokine systems such as the CCL2/CCR2 and CSF1/CSF1R pathways. After entering the tumor, monocytes differentiate into macrophages with a broad functional spectrum. A minority may retain inflammatory properties and release interleukin-1 beta, interleukin-27 and tumor necrosis factor. However, the review emphasizes that most adopt an anti-inflammatory and immunosuppressive state marked by PD-L1, transforming growth factor beta, interleukin-10 and arginase 1. These macrophages also promote blood-vessel formation through vascular endothelial growth factor and epidermal growth factor, while MMP2 helps remodel the extracellular matrix and opens pathways for invasion.

Other myeloid populations further reinforce this immune barrier. Neutrophils can be drawn into the glioma microenvironment through interleukin-8 signaling, where they may encourage additional recruitment of neutrophils and monocytes. Their expression of arginase 1 can deprive T cells of essential metabolic resources and restrict their ability to proliferate. Yet the review highlights an important exception: hybrid dendritic-like neutrophils may possess antitumor properties by presenting signals that prime T-cell cytotoxicity and support immune memory. Myeloid-derived suppressor cells, or MDSCs, are recruited through CCL2 and stromal cell-derived factor 1 alpha, also known as SDF-1α. They suppress adaptive immunity using arginase 1, inducible nitric oxide synthase, PD-L1 and transforming growth factor beta.

Dendritic cells, which normally function as professional antigen-presenting cells, are also undermined by the glioma environment. Tumor-derived vascular endothelial growth factor, interleukin-6 and interleukin-10 can interfere with dendritic-cell maturation and reduce their capacity to process and present tumor antigens. Without effective antigen presentation, T cells are not properly activated against malignant cells. Even when T cells do enter the tumor, they frequently encounter an environment dominated by inhibitory signals. Repeated engagement between PD-1 on T cells and PD-L1 on tumor or immune cells can drive exhaustion or apoptosis, while transforming growth factor beta and indoleamine 2,3-dioxygenase 1 further suppress T-cell metabolism and function. This helps explain why immune infiltration does not necessarily translate into tumor control.

The neural nature of the brain adds another layer of complexity. Research summarized in the review shows that glioma cells can form functional excitatory synapses with neurons. Through these connections, neuronal activity and neurotransmitters such as glutamate can directly stimulate tumor-cell signaling and growth. Glioma cells may also exploit gamma-aminobutyric acid and neurotrophic factors, including neuroligin-3, brain-derived neurotrophic factor, insulin-like growth factor 1 and semaphorin 4F. Neuroligin-3 is particularly important because neuronal activity can trigger its release, activating growth programs in glioma cells. This creates a feed-forward loop in which active neural circuits promote tumor expansion, while the expanding tumor becomes increasingly integrated into the surrounding brain network.

Astrocytes and oligodendrocyte-lineage cells are similarly drawn into the tumor-supporting system. Reactive astrocytes can communicate with glioma cells through gap junctions, allowing direct exchange of ions and signaling molecules. Additional interactions involving interleukin-11 and its receptor, as well as annexin A1-related signaling, may promote invasion and suppress T-cell immunity. Although the review gives less emphasis to oligodendrocyte-lineage cells, it identifies them as additional participants in glioma progression, with potential roles in angiogenesis and immune escape. Together, these findings challenge the traditional view that the malignant cell is the only biologically relevant target inside the brain.

The vascular system provides both nutrients and a route for tumor dissemination. Glioma-associated endothelial cells respond to vascular endothelial growth factor and fibroblast growth factor, driving the formation of abnormal blood vessels. These vessels are often tortuous, structurally fragile and poorly organized. Their dysfunction disrupts the blood-brain barrier, increasing the movement of peripheral immune cells into the tumor while simultaneously creating profound therapeutic obstacles. Abnormal perfusion can produce regions of hypoxia and impaired drug distribution, meaning that a medicine may reach some tumor compartments but fail to penetrate others. Lymphatic endothelial cells may also participate directly in tumor progression through the CCL21/CCR7 signaling axis, adding another route of communication between glioma cells and the surrounding tissue.

The review argues that these interconnected mechanisms demand a broader therapeutic strategy. Blocking tumor-cell proliferation alone may not be enough if microglia and macrophages remain immunosuppressive, neuronal activity continues to stimulate growth, and abnormal vessels prevent adequate drug delivery. Potential approaches include reprogramming tumor-associated macrophages, inhibiting monocyte recruitment through the CCL2/CCR2 or CSF1/CSF1R axes, targeting MDSCs, restoring dendritic-cell function and combining immune checkpoint blockade with methods that reverse T-cell exhaustion. Interfering with neuron-glioma synapses, neuroligin-3 signaling, glutamatergic stimulation or astrocyte-mediated communication could provide additional ways to disrupt the tumor’s neural support system. The authors present the glioma microenvironment not only as the central engine of therapeutic resistance but also as a source of new vulnerabilities. By dismantling the ecosystem that protects malignant cells, future treatments may move beyond attacking the tumor in isolation and instead disable the biological network that allows it to survive.

Subject of Research: Glioma tumor microenvironment and cellular crosstalk

Article Title: Glioma Microenvironment: Cellular Crosstalk, Immunosuppression, and Novel Therapeutic Perspectives

News Publication Date: 15 June 2026

Web References: https://doi.org/10.1097/CM9.0000000000004151

References: Zhao L. “Glioma Microenvironment: Cellular Crosstalk, Immunosuppression, and Novel Therapeutic Perspectives.” Chinese Medical Journal. DOI: 10.1097/CM9.0000000000004151

Image Credits: Chinese Medical Journal

Keywords: glioma, brain cancer, tumor microenvironment, neuro-oncology, microglia, macrophages, immunosuppression, T-cell exhaustion, glioma immunotherapy, neuron-tumor communication, astrocytes, tumor-associated macrophages, blood-brain barrier, cancer neuroscience